linjc16/ctgov huggingface dataset:
Reflectance Confocal Microscopy of Wounds During Moh's Surgery: Feasibility Testing of a Mosaicing Algorithm for Intraoperative Imaging of Cancer Margins

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate a new instrument that shines light and takes digital pictures of skin. The goal is to develop a technique that may enable fast and accurate assessment of surgical margins in the excision of basal cell carcinoma (BCC) or squamous cell carcinoma (SCC). The investigators will evaluate the pictures obtained by the confocal microscope to determine whether this technique may be useful in the future for helping Mohs surgeons remove cancers. In the future, patients may benefit with shorter surgery and improved care.

Official Title
-----------------
Reflectance Confocal Microscopy of Wounds During Moh's Surgery: Feasibility Testing of a Mosaicing Algorithm for Intraoperative Imaging of Cancer Margins

Conditions
-----------------
Basal Cell Carcinoma, Squamous Cell Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing Mohs surgery for basal cell carcinoma (BCC )or squamous cell carcinoma (SCC). . Ability to sign informed consent. Age ≥ 18 years. Exclusion Criteria: Mohs surgery located on a site that may not be convenient to confocal imaging. Inability to give informed consent. Inability to tolerate imaging procedure (i.e., remain relatively still for multiple short durations of 3-4 minutes) over a total time of 20 minutes.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| test feasibility of a mosaicing algorithm intraoperative | For the primary study objective, the Mohs surgeon will perform a qualitative assessment of the confocal mosaic. This will be a dichotomous assessment of whether the mosaic is of sufficient quality (contrast and resolution) to identify individual features. The specific features for BCC or SCC margins are tumor nests with nuclear atypia and increased nuclear density (relative to the density seen in normal basal cells). | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| test feasibility of a mosaicing algorithm preoperative | imaging of cancer margins on patients, before Mohs surgery. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mosaicing algorithm, intraoperative imaging, 12-239, Moh's Surgery
Narrow-Band UVB-Therapy in Psoriasis

Study Overview
=================
Brief Summary
-----------------
Study on two different irradiation schemes in UVB phototherapy for psoriasis. Previous studies demonstrated a similar clinical effect in erythematogenic and suberythematogenic irradiation, with less complications in suberythematogenic irradiation. Most of these studies used both irradiation schemes within the same patient. UVB has a systemic effect on the body. Our hypothesis is that previous conclusions are incorrect and that the erythematogenic scheme will result in earlier clearance of the psoriasis.

Detailed Description
-----------------
109 psoriasis patients, referred for UVB phototherapy, participated in our study after given their written informed consent. After determining the minimal erythema dose (MED) patients were randomised in either group 1, erythematogenic scheme, or group 2, suberythematogenic scheme. Group 1 started with 70% of MED and every following irradiation with an increase of 40%. Group 2 started with 30% of MED and every next visit an increase of 20%. The study protocol was adjusted in case of erythema (sunburn) according to a standard erythema-phototherapy protocol, varying from skip one irradiation to lowering the percentage of increase. In case of clearance the study stopped. Clearance was defined as less than 10% of baseline body area of psoriasis.

Official Title
-----------------
Narrow-Band UVB-Therapy in Psoriasis: Randomised Double-Blind Comparison of Erythematogenic and Suberythematogenic Irradiation Regimens

Conditions
-----------------
Psoriasis

Intervention / Treatment
-----------------
* Procedure: UVB phototherapy
* Procedure: UVB phototherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eligible for UVB phototherapy Older than 18 years Exclusion Criteria: No topical medication for 2 weeks No systemic medication for 4 weeks No medication (betablocker, lithium) interfering with psoriasis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: group 1<br>Erythematogenic irradiation scheme | Procedure: UVB phototherapy<br>* Group 1: every irradiation an increase of 40%, starting with 70% of the minimal erythema dose<br>|
| Active Comparator: group 2<br>Suberythematogenic irradiation scheme | Procedure: UVB phototherapy<br>* Group 2: every irradiation an increase of 20%, starting with 30% of the minimal erythema dose<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clearance is defined as less than 10% affected body area with psoriasis compared with baseline |  | every 4 weeks |
Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.

Study Overview
=================
Brief Summary
-----------------
Study examining the effect of different diuretics on fluid retention in diabetics treated with rosiglitazone.

Detailed Description
-----------------
A randomised, open-label, parallel group study to evaluate the management of rosiglitazone-related fluid retention by investigating the effect of diuretics on plasma volume in subjects with type 2 diabetes mellitus treated for twelve weeks with rosiglitazone 4mg bd in addition to background anti-diabetic agents.

Official Title
-----------------
A Randomised Study Examining the Effect of Different Diuretics on Fluid Balance in Diabetics Treated With Avandia

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Drug: Rosiglitazone
* Drug: spironolactone
* Drug: hydrochlorothiazide
* Drug: frusemide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Subjects with type 2 diabetes. Stable FPG of >=7.0 and <=12.0mmol/L. Subjects had to have been established on SU treatment or SU+MET treatment for at least 2 months. Serum creatinine level > 130 micromol/L. Exclusion criteria: Subjects taking > 2 concomitant oral anti-diabetic agents. Subjects with HbA1c >=10%. Subjects already receiving diuretic medication. Subjects unstable or severe angina. CHF NYHA class i-iv. Subjects with clinically significant hepatic disease.

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Rosiglitazone|nan|
|Drug: spironolactone|nan|
|Drug: hydrochlorothiazide|nan|
|Drug: frusemide|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in Haematocrit following 7 days diuretic adminstration. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total body fluid & extracellular fluid, body weight, haematocrit & haemoglobin. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rosiglitazone, fluid retention, Type 2 diabetes, diuretics
Evaluation of the Overall Quality of Life After the Neck Dissection Retro-spinal Sector (IIb), in Squamous Cell Carcinomas Clinical and Radiological N0 VADS

Study Overview
=================
Brief Summary
-----------------
The nodal involvement in squamous cell carcinomas of the upper aerodigestive tract (VADS) is one of the main factors of poor prognosis, justifying the surgical management of neck dissection as a reference treatment. Under the influence of the American Hayes Martin, it was considered until the 1960s that over the intervention was, the greater the chance of recovery was. But has since been developed by the Argentine Osvaldo Suarez the concept of functional course, which consists of resection of lymph node tissue while retaining the main structures (muscles, nerves, vessels), as opposed to the recess radical which is reserved for the invasive metastasis. In addition to these notions, our job is to evaluate the quality of life of patients with SCCHN, N0 clinical and radiological, enjoying a functional neck dissection including IIb sector to support the approach which would be to stop the systematic inclusion of this territory.

Conditions
-----------------
SCCHN

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with SCCHN histologically proven N0 clinical and radiological Neoplastic Location: oral cavity, oropharynx, hypopharynx, larynx Patient candidate for a neck dissection fonctonnel Life expectancy> 3 months Stable patient not exhibiting at the time of recurrence sign of examination or other scalable neoplasia Age over 18 ans Patient was informed of the study Patient fluent French Exclusion Criteria: Patients with a history of malignancy, outside a basal cell cancer or cancer of the neck treated and cured Patient has at the time of examination of recurrence of signs or other scalable neoplasia Uncontrolled Infectious diseases Neoadjuvant radiotherapy Patient nursing or pregnant or lack of contraception during their reproductive Intercurrent pathology involving life-threatening Any medical or psychological condition associated that could compromise the patient's ability to participate in the study Inability to submit to medical follow-up study for geographical, social or psychic

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Annalogue Scale for Global Quality of Life | (rate between 0 and 10) | change over baseline and month 6 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
N0 clinical and radiological, dissection IIb sector
Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Multicenter Retrospective Study) III

Study Overview
=================
Brief Summary
-----------------
Anatomopathological classifications have been well identified in aortic dissection with important therapeutic implications. The authors evaluated the inflammatory response in patients with aortic dissection (AD) and assessed the presence of distinct inflammatory subphenotypes within this disease.

Official Title
-----------------
Inflammatory Response and Anti-inflammatory Action for Aortopathy & Arteriopathy (5A-Plan): A Multicenter Retrospective Study

Conditions
-----------------
Aortic Dissection

Intervention / Treatment
-----------------
* Biological: inflammatory response


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: acute type Aortic dissection; Exclusion Criteria: Iatrogenic aortic dissection OR traumatic aortic dissection Patients with hematological diseases, infectious diseases, malignant tumors, immune system diseases, or severe liver diseases. Preoperative use of mechanical ventilation, blood transfusion, renal replacement therapy, extracorporeal membrane oxygenation, or intra-aortic balloon pump during the current admission.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| inflammatory subphenotype<br> | Biological: inflammatory response<br>* laboratory data (leukocyte, neutrophils, monocyte, lymphocytes, platelet, fibrinogen, D-dimer, neutrophils-lymphocyte ratio, platelet-lymphocyte ratio, lymphocyte-monocyte ratio)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 30-day mortality | any cause death within 30 days of surgery | 30 days after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ICU mortality | any cause death within ICU | 7 days after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aortic Dissection, Inflammatory Response
Targeting Leukotrienes in Kidney Disease

Study Overview
=================
Brief Summary
-----------------
Diabetic kidney disease (DKD) is associated with significant morbidity and mortality. Identifying new treatments for DKD to be used alone or in combination with other therapies is a high priority. Inflammation plays a key role in DKD and targeting pro-inflammatory lipid mediators called leukotrienes may represent a promising therapy for DKD. The current proposal will investigate whether montelukast, a leukotriene antagonist, reduces proteinuria and improves vascular function and arterial stiffness in patients with DKD.

Official Title
-----------------
Targeting Leukotrienes in Kidney Disease: A Pilot Study

Conditions
-----------------
Diabetic Kidney Disease

Intervention / Treatment
-----------------
* Drug: Montelukast


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CKD stage 3 urine albumin to creatinine ratio 200-5000 mg/g blood pressure <140/90 mmHg use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker with stable dose for 4 weeks history of diabetes type 1 or 2 BMI <40 kg/m2 Stable antihypertensive regimen for at least one month prior to enrollment Stable diabetes regimen for at least one month prior to enrollment Sedentary or recreationally active (<2 days of vigorous aerobic exercise as vigorous exercise may affect vascular function measurements) Able to provide consent Exclusion Criteria: Significant comorbid conditions that lead the investigator to conclude that life expectancy is less than 1 year Uncontrolled hypertension Factors judged to limit adherence to interventions (e.g. history of medication noncompliance, noncompliance with follow up visits, significant cognitive impairment, etc.) Anticipated initiation of dialysis or kidney transplantation within 3 months Current participation in another research study Pregnancy or planning to become pregnant or currently breastfeeding Allergy to aspirin Severe hepatic impairment (Child-Pugh Class C) History of major psychiatric disorder Use of inhaled or systemic corticosteroids or long-acting beta agonists (higher risk of neuropsychiatric reaction) Current use of SGLT2 inhibitor Current use of phenobarbital, rifampin or carbamazepine.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: montelukast<br>montelukast 10mg orally once a day | Drug: Montelukast<br>* 10mg orally once a day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Albuminuria at 3 months | Change in 24-hour urine albumin excretion at 3 months | Baseline, 3 months |
Prevention of Ventilator-Associated Pneumonia by Automatic Control of the Tracheal Tube Cuff Pressure

Study Overview
=================
Brief Summary
-----------------
Background: The aspiration of contaminated secretions pooled above the endotracheal tube cuff secondary to inadvertent falls of cuff pressure is the main pathogenic mechanism of ventilator-associated pneumonia (VAP). Aim of the study: To assess the efficacy of an automatic device for the continuous regulation of tracheal tube cuff pressure in decreasing the incidence of VAP.

Detailed Description
-----------------
Design: Prospective, randomized, controlled trial, with 2 groups: study (automated control of cuff pressure) and control (standard control of cuff pressure). Setting: Respiratory Intensive Care Unit (RICU). Subjects: Patients >18 yr, intubated and ventilated. Interventions and measurements: Study group (cuff pressure will be kept constant at 25 cmH2O with the automatic device) and control group (cuff pressure control every 8 h. at the same level using a manual pressure controller, according with standard routine); recording of clinical variables at admission and during RICU stay, and end-point variables (incidence of VAP, etiologic microorganisms, RICU and hospital stay, RICU and 60-d mortality. Expected results: Lower incidence of VAP in study group, compared with control group.

Official Title
-----------------
Prevention of Ventilator-Associated Pneumonia by Automatic Control of the Tracheal Tube Cuff Pressure

Conditions
-----------------
Ventilator-Associated Pneumonia, Mechanical Ventilation

Intervention / Treatment
-----------------
* Device: Automatic control of tracheal tube cuff pressure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 18 years, Orotracheal intubation for less than 24 hours Expectancy to remain on mechanical ventilation for more than 48 hours Exclusion Criteria: Pneumonia Witnessed macroscopic aspiration

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Automatic control of tracheal tube cuff pressure|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of ventilator-associated pneumonia |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ventilator-associated pneumonia, Mechanical ventilation, Tracheal tube cuff pressure
Trigeminal Neuralgia Electrophysiology

Study Overview
=================
Brief Summary
-----------------
The study intervention is to perform standard somatosensory evoked responses limited to the face during rhizotomy procedures of the gasserian ganglion (trigeminal ganglion) for the treatment of trigeminal neuralgia. The evoked responses will be measured at two locations before and after the clinical rhizotomy including: the standard contralateral scalp (EEG) and at the gasserian ganglion through an FDA-approved recording electrode.

Official Title
-----------------
Trigeminal Evoked Responses to Improve Rhizotomy

Conditions
-----------------
Trigeminal Neuralgia

Intervention / Treatment
-----------------
* Procedure: Trigeminal Electrophysiology


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria (TGN): Adults of 18 years or older Scheduled to undergo percutaneous rhizotomy for facial pain Exclusion Criteria (TGN): Facial pain of unclear origin (i.e. not clearly TGN pain) Rhizotomy procedure canceled Inclusion Criteria (Healthy controls) Adults of 18 years or older Exclusion Criteria (Healthy Controls) Diagnosis or history of facial pain such as TMD or TGN History of migraine History of any functional pain disorder: fibromyalgia, IBS, CRPS Recent chronic pain (within last month) Unwilling to participate for two hours in lab Current acute pain

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Trigeminal Electrophysiology<br> | Procedure: Trigeminal Electrophysiology<br>* This study will pilot and test the feasibility of introducing electrophysiology into the routine rhizotomy procedure by including trigeminal somatosensory evoked potentials (TSEPs) and recording from electrodes at the level of the ganglion.<br>|
| Controls<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine the feasibility of measuring trigeminal somatosensory evoked potentials to improve personalized mapping during percutaneous rhizotomy | percentage of consented participants who complete the study | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Trigeminal Neuralgia